195 related articles for article (PubMed ID: 11793370)
21. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
24. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
26. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J
Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559
[TBL] [Abstract][Full Text] [Related]
27. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C
Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776
[TBL] [Abstract][Full Text] [Related]
28. [Frequent somatic mutations of the von Hippel-Lindau (VHL) tumor suppressor gene and its meaning in sporadic human renal clear cell carcinoma].
Gong K; Zhang N; Guo HF; Zhang ZW; Xin DQ; Na YQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):169-72. PubMed ID: 15100736
[TBL] [Abstract][Full Text] [Related]
29. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
30. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
31. Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma.
Barnabas N; Amin MB; Pindolia K; Nanavati R; Amin MB; Worsham MJ
J Surg Oncol; 2002 May; 80(1):52-60. PubMed ID: 11967908
[TBL] [Abstract][Full Text] [Related]
32. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
33. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
Richard S
Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
[No Abstract] [Full Text] [Related]
34. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
[TBL] [Abstract][Full Text] [Related]
35. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
[TBL] [Abstract][Full Text] [Related]
36. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
37. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
38. [Somatic mutations of VHL gene and HIF-1alpha expression in primary renal clear cell carcinomas].
Guo HF; Gong K; Zou SM; Zhang ZW; Liu XY; Na X; Wu G; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(4):196-200. PubMed ID: 15062033
[TBL] [Abstract][Full Text] [Related]
39. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C
Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
